Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Speciality MedicinesBOM:544738 -6.76%21 Pretax Margin % is 18.09% as of Mar. 2026, which is 21% above its 10-year median of 14.91. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Speciality Medicines ranks better than 77.48% on this metric.
The historical rank and industry rank for Speciality Medicines's Pretax Margin % or its related term are showing as below:
BOM:544738'
s Pretax Margin % Range Over the Past 10 Years
Min: 5.29 Med: 14.91 Max: 18.09
Current: 18.09
BOM:544738's Pretax Margin % is ranked better than 77.48% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.03
vs BOM:544738: 18.09
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Speciality Medicines Pretax Margin % Related Terms
Speciality Medicines Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Speciality Medicines's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines Pretax Margin % Chart
Speciality Medicines Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
Pretax Margin %
5.29
12.75
16.55
14.91
17.29
Speciality Medicines Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
Pretax Margin %
0.00
0.00
0.00
13.56
18.09
BOM:544738 vs ZTS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Speciality Medicines's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Speciality Medicines Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Speciality Medicines's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Speciality Medicines's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines (BOM:544738) has a Pretax Margin % of 18.09% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Speciality Medicines and its competitors. This is 21% above median its historical median of 14.91. Over the past decade, Speciality Medicines' Pretax Margin % has ranged from 5.29 to 18.09. According to the industry distribution chart, Speciality Medicines ranks #216 out of 959 companies in the Drug Manufacturers industry, placing it in the top 22.5%.
Is Speciality Medicines' Pretax Margin % too high?
Speciality Medicines' current Pretax Margin % of 18.09% is 21% above median its 10-year median of 14.91. Over the past 10 years, this metric has ranged from a low of 5.29 to a high of 18.09. The Drug Manufacturers industry median Pretax Margin % is 7.03. Speciality Medicines' value of 18.09% is 157.3% above this industry median. Based on the distribution chart, Speciality Medicines ranks #216 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Speciality Medicines ranks #216 out of 959 companies for Pretax Margin %. This places Speciality Medicines in the top 23% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.03. Speciality Medicines' value of 18.09% is 157.3% above this benchmark. Historically, Speciality Medicines' own Pretax Margin % has ranged from 5.29 to 18.09 over the past decade. While the company's 10-year median is 14.91 vs. the industry median of 7.03, Speciality Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Speciality Medicines's current Pretax Margin % of 18.09% is 157.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Speciality Medicines and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Speciality Medicines's current Pretax Margin % is 18.09%, which is 21% above median its own 10-year median of 14.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current Pretax Margin % of 18.09%. The current Pretax Margin % is 18.09%, which is 21% above median its 10-year median of 14.91 and 157.3% above the Drug Manufacturers industry median of 7.03. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current Pretax Margin % is 18.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score
Get the complete analysis for BOM:544738
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544738 has been successfully added to your 
